PARP抑制剂不良反应可能与药物在靶效应(on-target effect)和脱靶效应(off-target effect)相关,特点如下:(1)不同PARP抑制剂的不良反应特征相似,但不同药物具体的不良反应发生率、严重程度等存在各自特征[11]。在绝大多数药物相关的不良反应处理上,不同药...
The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals. Eur J Neurosci. 2004; 20 :1461–1472.Koh SH , Park Y , Song CW , Kim JG , Kim K , Kim J et al. ( 2004 ). The effect of PARP inhibitor on ischemic cell death, its related ...
PARP抑制剂不良反应可能与药物在靶效应(on-target effect)和脱靶效应(off-target effect)相关,特点如下:(1)不同PARP抑制剂的不良反应特征相似,但不同药物具体的不良反应发生率、严重程度等存在各自特征[11]。在绝大多数药物相关的不良反应处理上,不同药物可以遵循相同的处理原则,但某药物独有的不良反应应该采取独特...
The aim of our study was to evaluate whether PARP is expressed in post-ischemic liver, and to examine the effect of the administration of PJ-34 PARP inhibitor on liver function, histopathology, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) reaction, and the ...
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair. Here, we describe BMN 673, a novel, highly p... Y Shen,FL...
(1)Detection of the effect of PARP-1 inhibitor.After C. sinensis infection, the mice were treated with NMS-P 118 for 7 days, 15 days and 35 days, and the expression levels of PARP-1 and PAR in the liver were detected by western blot.The results showed that PARP-1 expression was sig...
(ANOVA)), suggesting a drug class effect. We also noted that Parp1 mutant ES cells exhibited enhanced sensitivity to camptothecin, a topoisomerase I inhibitor (Supplementary Figure1a), consistent with previous observations19,20. Taken together, these observations suggested that loss of Parp1 DNA ...
PARP inhibitor HR: Homologous recombination HRD: Homologous recombination repair deficient PARylation: ADP-ribosylation DDR: DNA damage response NHEJ: Non-homologous end joining repair SSBR: Single stranded break repair SSB: Single-strand breaks
Recently, a first-in-class ARH3 inhibitor was reported, and the availability of compounds abrogating the activity of dePARylating enzymes beyond PARG and ARH3 seems in reach [56]. PARP1 in DNA repair and chromatin remodeling In the context of DNA repair, the best-studied role of PARP1 ...
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors Article 17 June 2021 References Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005). CAS PubMed Go...